The Cardiovascular Disease Pipeline: A Strategic ReviewDecision ResourcesApril 27, 2009 30 Pages - SKU: DECR2272744 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
5/21/2012 | published by: GlobalData
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report
|
more...
|
$3,995.00
|
|
Targeted Health and Wellness Foods and Beverages: The U.S. Market and Global Trends
3/1/2012 | published by: Packaged Facts
The market for targeted health and wellness foods and beverages is a dynamic and promising one, driven largely by the growing recognition—among scientists, government, practitioners, and consumers alike—of the instrumental role diet plays in a
|
more...
|
$3,500.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Lung Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
Hepatic Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Hepatic Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Hepatic Injury Global Clinical Trials Review, H1, 2012 provides data on the Hepatic Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Clinical Trials Market in India 2012
4/13/2012 | published by: Netscribes (India) Pvt. Ltd.
The Indian clinical trials market is growing at an excellent rate and currently witnessing a large number of global pharmaceutical companies outsourcing trials to contract research organizations (CROs) in India. This is largely due to
|
more...
|
$795.00
|
|
Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2012
4/19/2012 | published by: Global Markets Direct
Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2012', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) therapeutic pipeline. This report provides information
|
more...
|
$500.00
|
Related Markets
Cardiovascular Reports
- Cardiovascular Partnering Terms and Agreements
- International Stroke Conference 2012 - Post-Conference Review and Analysis
- 6th Asian Pacific Congress of Heart Failure (APCHF) - Post-Conference Review and Analysis
- Arrhythmias Global Clinical Trials Review, H1, 2012
- Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018
